Company Overview of Oncopeptides AB
Oncopeptides AB is a clinical stage pharmaceutical development company that develops cytosuperior chemotherapeutic pharmaceuticals of existing basic cytotoxic compounds for cancer treatment. Its product includes Melflufen, a cytosuperior of the chemotherapeutic alkylator melphalan that is accumulated in cancer cells for targeting multiple myeloma. The company is headquartered in Stockholm, Sweden.
Västra Trädgårdsgatan 15
Stockholm, 111 53
46 7 05 69 54 71
Key Executives for Oncopeptides AB
Oncopeptides AB Key Developments
Similar Private Companies By Industry
|Aditech Pharma AB||Europe|
|Apotek Produktion & Laboratorier AB||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Sponsored Financial Commentaries
To contact Oncopeptides AB, please visit www.oncopeptides.se. Company data is provided by Capital IQ. Please use this form to report any data issues.